ASCO Genitourinary Symposium

Long-term follow-up of Nubeqa for nonmetastatic castration-resistant prostate cancer showed that the drug was safe and effective in treating this patient population.

After a patient receives a kidney cancer diagnosis, there are some important conversations to have with their health care team.

An expert explains what patients with low-grade prostate cancer can expect when undergoing genomic testing — and why the procedure is important.

Important data may encourage gender-specific treatment making decisions for patients with bladder cancer.

A clinical trial is currently enrolling patients who are experiencing hand-foot skin reaction as a result of kidney cancer treatment.

The addition of Tecentriq to platinum-based chemotherapy/gemcitabine did not boost outcomes in patients with metastatic bladder cancer, according to results from the IMvigor 140 trial.

The addition of Cabometyx to Opdivo and Yervoy improved outcomes for patients with advanced kidney cancer, according to recent research.

Researchers identified several biomarkers that may indicate how a patient responds to Padcev, a type of antibody drug conjugate for patients with urothelial carcinoma, a type of bladder cancer.

The combination demonstrated survival benefit in patients with metastatic hormone-sensitive prostate cancer, regardless of risk or volume of disease.

The administration of Pluvicto within six months of radium-223 treatment proved to be safe and efficacious in patients with metastatic castration-resistant prostate cancer, research showed.

Patients treated with Nubeqa were less likely to develop disease metastasis or discontinue treatment 6 to 18 months after ARI course start compared to Xtandi or Erleada, according to data presented at ASCO GU.

Patients treated with Lutetium-177 PSMA-617 tended to experience improvements in quality of life related to the aches and pains that can come from bone metastases.

In a recent clinical trial, treatment with Bavencio plus Inlyta produced promising outcomes in the presurgical treatment of patients with non-metastatic, clear cell renal cell carcinoma.

Treatment with Cabometyx before surgery in patients with advanced renal cell carcinoma, a type of kidney cancer, may provide benefits, although further research is required before a decision is made about its role in presurgical treatment.

Although the data failed to identify a predictive biomarker in patients with advanced kidney cancer, an expert from Memorial Sloan Kettering Cancer Center in New York notes that the results indicate that no one should be excluded from receiving Lenvima plus Keytruda.

Tecentriq failed to meet the progression-free survival goal in a trial analyzing the immunotherapy agent in advanced squamous cell carcinoma of the penis.

Patients with nonmetastatic castration-resistant prostate cancer who were taking other medications or had health complications still derived a survival benefit from treatment with Nubeqa, research showed.

Fotivda – a TKI drug that was approved last year – not only improved survival outcomes, but was also very tolerable in terms of side effects for patients with metastatic renal cell carcinoma.

Positive results from the phase 3 CLEAR clinical trial, presented at the 2021 ASCO Genitourinary Cancers Symposium, are just one more dataset that could offer “a sense of hope and promise” for patients with advanced renal cell carcinoma (RCC), says the study’s lead author, Dr. Robert J. Motzer.

The study results, according to one expert, show that Cabometyx should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma.

Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.

The results of the phase 3 trial, according to one expert, support the use of Lenvima with Keytruda as a possible first-line treatment option for patients with advanced renal cell carcinoma.

Treatment with sapanisertib was associated with limited activity and poor safety outcomes in patients with refractory metastatic renal cell carcinoma.

For patients to maintain or improve their quality of life through their cancer treatment, it is pivotal that they communicate with their health care team.

Clinical trials remain the gold standard when it comes to finding new treatment options for patients, particularly when it comes to renal cell carcinoma. But even if the results are positive and this combination proves to be beneficial, patients should still discuss all of their options with their oncologist to find the right sequence of treatment, says one expert.

The combination of Erleada, Zytiga and the steroid prednisone was associated with a trend toward better survival outcomes in certain patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

Front-line treatment with Opdivo plus Cabometyx improved health-related quality of life outcomes in patients with advanced renal cell carcinoma.

Patients with metastatic non–clear cell renal cell carcinoma who receive immune checkpoint inhibitor–based regimens as a first treatment option may have improved survival, versus those who receive select targeted therapies.

A higher starting dose of Lenvima, compared with a lower starting dose, prolonged the time that patients with renal cell carcinoma experienced negative effects on factors including social and physical functioning, financial difficulties and cogitative functioning over time.

The combination of Lenvima plus everolimus was found to be an acceptable treatment option for patients who have previously received immunotherapy for clear cell renal cell carcinoma, according to the findings of an exploratory analysis of a phase 2 trial presented virtually at the 2021 ASCO Genitourinary Cancers Symposium.